JeffreyMichaelSobellMD

PubMed

• 1 citations
  Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021.
  Christine Learned, Sara Alsukait, Sandhya Deverapalli, Erika Elliott, Katherine Moody, Jeffrey Sobell, Nellie Konnikov, Melissa Ortega, David Rosmarin> ;JAAD International. 2022 Jun 1
• 2 citations
  Defining drug-free remission of skin disease in patients with plaque psoriasis.
  April W. Armstrong, Andrew Blauvelt, Jeffrey J. Crowley, Kenneth B. Gordon, Gerald G. Krueger, James G. Krueger, Jeffrey M. Sobell, Bruce Strober, Bhaskar Srivastava, ...> ;The British Journal of Dermatology. 2020 Jun 1
• 11 citations
  Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice
  Alexa B. Kimball, Jeffrey J. Crowley, Kim Papp, Brian M. Calimlim, Yinghui Duan, A.B. Fleischer, Jeffrey M. Sobell> ;Journal of the European Academy of Dermatology and Venereology. 2020 Mar 1
• 46 citations
  Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlle...
  Luis Puig, Mark Lebwohl, Hervé Bachelez, Jeffrey M. Sobell, Abby Jacobson> ;Journal of the American Academy of Dermatology. 2020 Feb 1
• Using targeted therapies for inflammatory dermatoses.
  Jeffrey M. Sobell> ;Seminars in Cutaneous Medicine and Surgery. 2018 Sep 1
• 23 citations
  Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
  Caitriona Ryan, Jeffrey M. Sobell, Craig L. Leonardi, Charles Lynde, M. Karunaratne, Wendell C. Valdecantos, Barbara Hendrickson> ;American Journal of Clinical Dermatology. 2018 Jun 1
• 4 citations
  Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
  Evangelos J Giamarellos-Bourboulis, Jeffrey M. Sobell, Caitriona Ryan, Pierre J Wolkenstein, Ziqian Geng, Gerit Mulder> ;Wounds. 2017 Nov 1
• 3 citations
  Update on TNF Inhibitors in Dermatology.
  Jeffrey M. Sobell> ;Seminars in Cutaneous Medicine and Surgery. 2016 Jun 1
• 45 citations
  Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
  Jeffrey M. Sobell, Peter Foley, Darryl Toth, Ulrich Mrowietz, Giampiero Girolomoni, Joana Carla Soares Gonçalves, Robert M. Day, Rongdean Chen, Gil Yosipovitch> ;Acta Dermato-Venereologica. 2016 May 1
• 125 citations
  HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the place...
  Alexa B. Kimball, Jeffrey M. Sobell, Christos C. Zouboulis, Yihua Gu, David A. Williams, Murali Sundaram, Henrique D. Teixeira, Gregor B.E. Jemec> ;Journal of the European Academy of Dermatology and Venereology. 2016 Jun 1
• 1 citations
  The role of TNF inhibitors in psoriatic disease.
  Brian F. Mandell, Jeffrey M. Sobell> ;Seminars in Cutaneous Medicine and Surgery. 2014 Jun 1
• 8 citations
  Therapeutic development in psoriasis.
  Jeffrey M. Sobell, Craig L. Leonardi> ;Seminars in Cutaneous Medicine and Surgery. 2014 Jun 1
• 45 citations
  Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab...
  Bruce Strober, Jeffrey M. Sobell, Kristina Callis Duffin, Y. Bao, Annie Guerin, Hongbo Yang, O.M. Goldblum, Martin M. Okun, Parvez Mulani> ;The British Journal of Dermatology. 2012 Dec 1
• 38 citations
  Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosin...
  C. Leonardi, Jeffrey M. Sobell, Jeffrey J. Crowley, Ulrich Mrowietz, Y. Bao, Parvez Mulani, Yihua Gu, Martin M. Okun> ;The British Journal of Dermatology. 2012 Sep 1
• 6 citations
  A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2
  Bruce Strober, Jennifer Clay Cather, David E. Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Neil J. Korman, Gerald G. Krueger, Cra...> ;Dermatology and Therapy. 2012 Mar 30
• 17 citations
  A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1
  Bruce Strober, Jennifer Clay Cather, David E. Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Neil J. Korman, Gerald G. Krueger, Cra...> ;Dermatology and Therapy. 2012 Mar 17
• 18 citations
  A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
  Bruce Strober, Emily M. Berger, Jennifer Clay Cather, David E. Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Elizabeth J. Horn, Arthur Kavanaugh, Ne...> ;Journal of the American Academy of Dermatology. 2009 Jul 1
• 13 citations
  Patient fatalities potentially associated with efalizumab use.
  Jeffrey M. Sobell, Jeffrey M Weinberg> ;Journal of Drugs in Dermatology. 2009 Mar 1
• 9 citations
  Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents.
  Jeffrey M. Sobell, Robert E Kalb, Jeffrey M Weinberg> ;Journal of Drugs in Dermatology. 2009 Mar 1
• 11 citations
  Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
  Jeffrey M. Sobell, Robert E Kalb, Jeffrey M Weinberg> ;Journal of Drugs in Dermatology. 2009 Feb 1
• 5 citations
  Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
  Tiffani K. Hamilton, Alan Menter, Ivor Caro, Peter Compton, Jeffrey M. Sobell, Kim A. Papp> ;Drug Safety. 2008 Jan 1
• 24 citations
  Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.
  Alexa B. Kimball, Jeffrey M. Sobell, Boh Ee, Grekin S, Pharmd Eb, Woolley Jm, Xia Ha, Chiou Cf, Stevens> ;Journal of Drugs in Dermatology. 2007 Mar 1
• 16 citations
  Successful treatment of hand and foot psoriasis with efalizumab therapy.
  Scott Fretzin, Jeffrey J. Crowley, Loretta Jones, Melodie Young, Jeffrey M. Sobell> ;Journal of Drugs in Dermatology. 2006 Oct 1
• 5 citations
  Successful treatment of a widespread inflammatory verrucous epidermal nevus with etanercept.
  Melissa A. Bogle, Jeffrey M. Sobell, Jeffrey S. Dover> ;Archives of Dermatology. 2006 Mar 1
• 5 citations
  Overview of biologic agents in medicine and dermatology.
  Jeffrey M. Sobell> ;Seminars in Cutaneous Medicine and Surgery. 2005 Mar 1
• Join now to see all